the biotechs have come back into favor, rejenner on, celgene. it's more friendly environment makes it easier to buy stocks like portola hand over fist when certainly's going right. a lot has gone right in the past few months they made a deal with health care royalty, in exchange for 50 million up front and more if it gets fda approval. then we got encouraging signs on byvexa, the anti-clotting therapy and a little less than a month ago, the regulators flat out gave the drug their approval bevyxxa is going to roll out sometime this fall and it's huge it's much better than any anti-coagulants on the market. the stock rallied 46% in three